{"preliminary_commentary":{"by_channel":{"x_thread":72,"youtube":53,"podcast":34,"bluesky_thread":3,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03778957\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"EMERALD-1","nct_id":"NCT03778957","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=emerald-1-nct03778957. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"EMERALD-1","arms":[{"description":"Transarterial Chemoembolization (TACE) in combination with Durvalumab","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Transarterial Chemoembolization (TACE) in combination with Durvalumab and Bevacizumab","label":"Arm B","type":"EXPERIMENTAL"},{"description":"Transarterial Chemoembolization (TACE) in combination with Placebos","label":"Arm C","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-08-31","type":"ESTIMATED"},"conditions":["Hepatocellular Carcinoma"],"enrollment":{"count":724,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Bevacizumab","otherNames":["AVASTIN"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"OTHER"},{"name":"Transarterial Chemoembolization (TACE)","otherNames":[],"type":"PROCEDURE"}],"last_update":"2026-07-15","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination With Either Durvalumab Monotherapy or Durvalumab Plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-09-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) for Arm B vs Arm C","timeFrame":"Approximately 5 years"}],"references":[{"citation":"Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Zotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R; EMERALD-1 Investigators. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025 Jan 18;405(10474):216-232. doi: 10.1016/S0140-6736(24)02551-0. Epub 2025 Jan 8.","pmid":"39798579","type":"DERIVED"},{"citation":"Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1:137-149. doi: 10.1002/hep.31424. Epub 2020 Nov 6. No abstract available.","pmid":"32557715","type":"DERIVED"}],"start_date":{"date":"2018-11-30","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma","url":"https://clinicaltrials.gov/study/NCT03778957"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/emerald-1-nct03778957"}